Physician profile
Vance E Wilson
NPI 1487614947
$299,675.52
in general payments reported to CMS, 2019-2025
42 companies · $3,674 in 2025
The $3,674 reported for 2025 was more than what 79% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176K · 2020: $55K · 2021: $28K · 2022: $31K · 2023: $2,860 · 2024: $3,535 · 2025: $3,674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,830 · Food and Beverage: $1,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,830.00 |
| Food and Beverage | $1,240.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $160,284.39 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $57,298.41 | 2019-2025 | |
| Akcea Therapeutics, INC. | $20,599.64 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $18,495.71 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $13,123.68 | 2021-2025 | Verquvo |
| Regeneron Pharmaceuticals, INC. | $11,576.58 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $6,519.36 | 2019-2022 | |
| Boston Scientific Corporation | $6,402.14 | 2019-2022 | |
| Medtronic, INC. | $3,786.56 | 2021-2025 | Linq II |
| Alnylam Pharmaceuticals INC. | $186.67 | 2019-2025 | Amvuttra, Onpattro |
| Abbott Laboratories | $171.81 | 2020-2024 | Amplatzer Amulet |
| Abiomed | $134.25 | 2019-2023 | Impella |
| Celonova Biosciences, INC. | $100.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.07 | 2021-2023 | Jardiance |
| Innovation Technologies INC | $92.02 | 2021 |
Show all 38 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vance Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.